Momotaro Gene Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 10

Momotaro Gene General Information

Description

Developer of cancer therapeutic drug intended to research and commercialize cancer suppressor genes for curative purposes. The company's drug offers Reduced Expression in Immortalized Cell (REIC) gene drug is administered in the human body, which then assists the body to fight cancer cells, enabling doctors to assist cancer patients effectively.

Contact Information

Website
www.mt-gene.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th floor, Okayama Yanagimachi Building
  • 1-12-1 Yanagi-machi, Kita-ku
  • Okayama, 700-0904
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4th floor, Okayama Yanagimachi Building
  • 1-12-1 Yanagi-machi, Kita-ku
  • Okayama, 700-0904
  • Japan
+81

Momotaro Gene Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Momotaro Gene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 01-Mar-2023 Completed Generating Revenue
4. Later Stage VC 14-Dec-2020 Completed Generating Revenue
3. Later Stage VC 15-Mar-2019 Completed Generating Revenue
2. Later Stage VC (Series A) 26-Dec-2017 $10.4M $11.6M Completed Pre-Clinical Trials
1. Seed Round 22-Jul-2016 $1.21M $1.21M Completed Pre-Clinical Trials
To view Momotaro Gene’s complete valuation and funding history, request access »

Momotaro Gene Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preferred C
Preferred B
Preferred A 4,672 $2399.52 $2399.52 1x $2399.52 36.09%
To view Momotaro Gene’s complete cap table history, request access »

Momotaro Gene Patents

  • 101

    Total Documents Applications and Grants

  • Total Patents Families

  • 77

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

Momotaro Gene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4190362-A1 Agent including reic/dkk-3 gene for treating egfr gene mutation positive lung cancer Pending 31-Jul-2020
US-20230310653-A1 Therapeutic agent for egfr gene mutation-positive lung cancer comprising reic/dkk-3 gene Pending 31-Jul-2020
EP-4008349-A1 Method for treating liver cancer with combined use of reic/dkk-3 gene and anti-tumor agent Pending 31-Jul-2019
US-20220280601-A1 Method for treatment of hepatic cancer using reic/dkk-3 gene in combination with anti-tumor agent Pending 31-Jul-2019
EP-4008349-A4 Method for treating liver cancer with combined use of reic/dkk-3 gene and anti-tumor agent Pending 31-Jul-2019 A61K48/005
To view Momotaro Gene’s complete patent history, request access »

Momotaro Gene Executive Team (4)

Name Title Board Seat
Hitoshi Shiomi President, Chief Executive Officer & Board Member
Shinichi Yamamoto Chief Financial Officer & Board Member
Hiromi Kumon Chief Scientific Officer & Board Member
You’re viewing 3 of 4 executive team members. Get the full list »

Momotaro Gene Board Members (8)

Name Representing Role Since
Hiroki Narita Self Board Member
Hiromi Kumon Momotaro Gene Chief Scientific Officer & Board Member
Hiroshi Goshima Self Board Member & External Auditor
Masahumi Konishi Self Board Member & External Auditor
Naoki Noda Self Board Member & External Auditor
You’re viewing 5 of 8 board members. Get the full list »

Momotaro Gene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Momotaro Gene Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Iyogin Capital Venture Capital Minority
EPS Corporation Minority
Hiroshima Venture Capital Venture Capital Minority
SMBC Venture Capital Corporate Venture Capital Minority
BiGEN (Seoul) Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Momotaro Gene FAQs

  • When was Momotaro Gene founded?

    Momotaro Gene was founded in 2007.

  • Who is the CEO of Momotaro Gene?

    Hitoshi Shiomi is the CEO of Momotaro Gene.

  • Where is Momotaro Gene headquartered?

    Momotaro Gene is headquartered in Okayama, Japan.

  • What is the size of Momotaro Gene?

    Momotaro Gene has 7 total employees.

  • What industry is Momotaro Gene in?

    Momotaro Gene’s primary industry is Drug Discovery.

  • Is Momotaro Gene a private or public company?

    Momotaro Gene is a Private company.

  • What is Momotaro Gene’s current revenue?

    The current revenue for Momotaro Gene is .

  • How much funding has Momotaro Gene raised over time?

    Momotaro Gene has raised $17.2M.

  • Who are Momotaro Gene’s investors?

    Iyogin Capital, EPS, Hiroshima Venture Capital, SMBC Venture Capital, and BiGEN (Seoul) are 5 of 10 investors who have invested in Momotaro Gene.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »